Aripiprazole
Pre-clinicalTerminated 0 watching 0 views this week๐ค Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tourette's Syndrome
Conditions
Tourette's Syndrome
Trial Timeline
Jan 1, 2004 โ Oct 1, 2006
NCT ID
NCT00282139About Aripiprazole
Aripiprazole is a pre-clinical stage product being developed by Bristol Myers Squibb for Tourette's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282139. Target conditions include Tourette's Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01386086 | Phase 3 | Completed |
| NCT00665444 | Pre-clinical | Terminated |
| NCT00308074 | Phase 2 | Completed |
| NCT00619190 | Phase 2 | Completed |
| NCT00608543 | Approved | Completed |
| NCT00312598 | Pre-clinical | Completed |
| NCT00221416 | Phase 3 | Completed |
| NCT00221962 | Approved | Completed |
| NCT00209027 | Pre-clinical | Terminated |
| NCT00438386 | Approved | Completed |
| NCT00374348 | Pre-clinical | Completed |
| NCT00208169 | Approved | Completed |
| NCT00220636 | Approved | Completed |
| NCT00198055 | Phase 2 | Completed |
| NCT00250705 | Approved | Completed |
| NCT00222833 | Approved | Completed |
| NCT00223496 | Approved | Completed |
| NCT00226317 | Pre-clinical | Completed |
| NCT00194038 | Approved | Completed |
| NCT00224822 | Approved | Completed |
Competing Products
2 competing products in Tourette's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PF-03654746 + Placebo + Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| Tetrabenazine MR + Placebo | Bausch Health | Phase 2 | 47 |